Workflow
佳兆业健康(00876) - 2022 - 年度财报
KAISA HEALTHKAISA HEALTH(HK:00876)2023-04-28 08:46

Financial Performance - The company reported revenue of approximately HKD 191.5 million for the year ended December 31, 2022, a decrease of 8.65% compared to HKD 209.6 million in 2021[5]. - The loss attributable to shareholders was approximately HKD 123.3 million, translating to a basic loss per share of HKD 0.0245, compared to a profit of HKD 2.4 million and earnings per share of HKD 0.0005 in 2021[5][17]. - The company does not recommend a dividend for the year due to the reported losses[5]. - Gross profit for the year was HKD 82.6 million, down from HKD 97.4 million in the previous year, resulting in a gross margin decrease to 43.1% from 46.5%[35]. - The company's revenue for the year slightly decreased due to the ongoing adverse effects of the COVID-19 pandemic, with total sales impacted[34]. Business Expansion and Development - The dental business continues to grow steadily, with a sales service network covering major cities in China and partnerships with over 2,000 institutions[6]. - The company plans to expand its sales network in both domestic and overseas markets, including the United States, and increase production capacity in China[10]. - The newly launched transparent aligners have shown strong performance in driving revenue growth[10]. - The rehabilitation business is expanding with three clinics operating in key districts of Shenzhen, focusing on various rehabilitation services[8][12]. - The company plans to open 1-2 community rehabilitation centers in 2023, leveraging community resources from the Kaisa Group to expand its market presence in South China[32]. Research and Development - Research and development expenditure for the dental business was HKD 17.4 million in 2022, slightly up from HKD 17.2 million in 2021, indicating a commitment to future technology investment[20]. - The company has applied for 9 new patents and completed 3 medical device import registration certificates in China, enhancing its research and development capabilities[21]. - Research and development expenses are focused on enhancing future product competitiveness, including investments in 3D printing technology and invisible orthodontics software[38]. - The company aims to enhance R&D investment and innovation, introducing high-value products to meet growing dental and rehabilitation needs[145]. Health Business Performance - The health business incurred an operating loss of approximately HKD 32.4 million for the year ended December 31, 2022, due to delays in development plans caused by the COVID-19 pandemic[23]. - The company recorded an impairment loss of approximately HKD 73.4 million related to right-of-use assets, properties, and equipment in the health business for the year ended December 31, 2022[23]. - The company expects to generate a contract sales scale of RMB 160 million in 2023 from the health business, driven by the integration of organic agriculture, tourism, and health services[31]. Corporate Governance - The company emphasizes effective corporate governance as a key factor for maintaining development and enhancing shareholder value[72]. - The board has not authorized any other significant investments or additional capital asset plans as of the report date[54]. - The company has engaged an independent international auditing firm for annual internal control audits, despite lacking an internal audit function[72]. - The company has established three committees: the nomination committee, remuneration committee, and audit committee to oversee specific areas of governance[103]. - The board is responsible for maintaining an effective internal control system, which was reviewed by an independent international auditing firm for the year ended December 31, 2022[110]. Environmental, Social, and Governance (ESG) Initiatives - Kaisa Health Group reported a commitment to sustainable development, integrating ESG responsibilities into its core business operations[143]. - The company aims to create long-term value for stakeholders while fulfilling environmental and social responsibilities[145]. - The board is responsible for assessing and determining ESG-related risks and opportunities, ensuring effective risk management and internal control systems[149]. - The company achieved a waste reduction, with non-hazardous waste decreasing to 5.5 tons in 2022 from 64.4 tons in 2021, a reduction of 91.5%[166]. - The company strictly adhered to various environmental laws and regulations during the reporting period, including the Environmental Protection Law and the Air Pollution Prevention Law[167]. Employee Management and Safety - The group had approximately 940 employees across Hong Kong, China, and the United States as of December 31, 2022, an increase from approximately 700 employees in the previous year[55]. - The company has established a "Fair Treatment Policy" to promote equality among employees regardless of ethnicity, gender, or other protected statuses[185]. - The company has a zero fatality rate from occupational accidents over the past three years[191]. - The company provided training to 93% of male employees and 100% of female employees, with an average training duration of 6.8 hours for males and 6.3 hours for females[194]. - The company has implemented a comprehensive employee safety training program, including regular fire drills and emergency response training[190]. Supply Chain Management - The group collaborates with 72 suppliers in China and 1 supplier in North America[198]. - All suppliers must sign a Social Responsibility Management Commitment to meet environmental and labor standards[197]. - Suppliers are required to complete an Environmental Factors Survey to assess their operational impact on the environment[197]. - The group prioritizes suppliers with minimal negative environmental impact and those certified in ISO14001, ISO9001, and OSHMS[197].